載入...
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study
BACKGROUND: SPRINT-2 demonstrated that boceprevir (BOC), an oral hepatitis C virus (HCV) nonstructural 3 (NS3) protease inhibitor, added to peginterferon alfa-2b (P) and ribavirin (R) significantly increased sustained virologic response rates over PR alone in previously untreated adult patients with...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3643851/ https://ncbi.nlm.nih.gov/pubmed/23621902 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2334-13-190 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|